Vifo Screening and Foreign Investments in Dutch Acquisitions

How Dutch FDI screening affects SPA drafting, timing and closing certainty

Vifo screening in Dutch acquisitions is the national-security review of certain investments, mergers and acquisitions involving vital providers, sensitive technology, business campuses or other activities that may affect Dutch national security.

For foreign buyers, Vifo is not only a regulatory filing question. It is a transaction execution issue. If a Dutch target may fall within the scope of the Vifo Act, the screening analysis should be built into due diligence, SPA drafting, signing-to-closing planning and post-closing governance assumptions.

This article is part of my series on M&A Insights: Dutch deal practice for buyers, sellers and investors. It should be read together with practical cross-border deal examples such as Dutch Government Blocks Kyndryl’s Acquisition of Solvinity and Nexperia/Wingtech: When a Foreign Parent Clashes with a Dutch Strategic-Tech Subsidiary.

Why Vifo matters in M&A practice

Dutch M&A has traditionally been shaped by corporate law, employment law, tax, competition law, notarial execution and SPA risk allocation. Vifo adds another layer where national-security interests may affect whether a transaction can complete, on what timeline and subject to which conditions.

The practical issue is not limited to classic defence assets. Deal teams should pay attention to strategic technology, semiconductors, cybersecurity, digital infrastructure, sensitive data, energy, transport, financial infrastructure, business campuses and other activities that may be relevant to national security or security of supply.

The buyer’s nationality or ownership structure can also matter. A foreign buyer with a complex group structure, state-linked shareholders, sensitive jurisdictions or strategic technology interests may face a different risk profile from a purely domestic buyer.

Scope analysis should start early

A Vifo analysis should not wait until the SPA is almost agreed. It should start during initial structuring and due diligence.

The key questions are whether the target is active in a covered sector, whether the transaction gives the buyer control or significant influence, whether sensitive technology is involved, whether essential assets are being transferred, and whether the buyer’s ownership or governance rights create national-security concerns.

This analysis requires more than reviewing the target’s trade register description. The actual business activities, technology, customers, data, licences, supply-chain role, public-sector exposure and group dependencies should be reviewed.

In technology transactions, the hardest question is often not whether the company is “a tech company”. The harder question is whether the specific technology, data or operational capability is sensitive enough to trigger notification or scrutiny.

SPA conditions precedent and timing

If a filing may be required, the SPA should contain a specific condition precedent for obtaining clearance or confirmation that the transaction may proceed.

The drafting should address who is responsible for the filing, what cooperation is required, who controls communications with the authorities, what information the seller must provide, how long the parties will wait and what happens if clearance is conditional.

Long-stop dates require particular attention. Vifo timing can be difficult to predict, especially where additional information is requested or where the transaction is politically or strategically sensitive. A long-stop date that is too short may create unnecessary termination risk. A long-stop date that is too long may be commercially unacceptable to the seller.

The SPA should also address whether the buyer must accept remedies or commitments. That is often the real negotiation point. A buyer may be willing to file, but not to accept governance restrictions, divestments, information barriers or operational commitments that undermine the commercial rationale of the acquisition.

Closing risk and standstill

Where a transaction is notifiable, parties should not assume that they can close first and address screening later. Vifo-style screening is an execution constraint, not an administrative afterthought.

This affects closing mechanics. The notarial deed of share transfer, funds flow, repayment of existing debt, release of security, director changes and post-closing integration steps may all need to wait until the relevant condition is satisfied.

Foreign buyers should therefore coordinate the Vifo workstream with notarial execution and financing. A regulatory clearance delay can affect acquisition debt, foreign exchange planning, integration timetable, employee communications and customer messaging.

Information rights and interim covenants

Between signing and closing, buyers often want information about the target. In sensitive transactions, information rights themselves may need careful drafting.

The buyer may need access to business plans, customer information, technical documentation, cybersecurity materials, IP records, management reports or regulatory correspondence. The seller may need to restrict access to sensitive technology, classified information, export-controlled data, customer data or competitively sensitive information.

The SPA should therefore regulate interim information access with precision. Clean teams, redacted materials, staged disclosure and specific confidentiality protocols may be appropriate.

Interim covenants also need attention. The seller should operate the business in the ordinary course, but the buyer may want veto rights over material decisions. In a Vifo-sensitive transaction, those veto rights should not accidentally give the buyer control before clearance.

Buyer covenants and regulatory remedies

Buyer covenants are central in Vifo-sensitive deals. The seller will want the buyer to take all reasonable steps to obtain clearance. The buyer will want to avoid an obligation to accept any remedy, condition or restriction regardless of commercial impact.

The drafting should distinguish between reasonable cooperation, information provision, regulatory engagement, mitigation commitments and substantive remedies. The buyer may accept procedural obligations but resist material divestments, technology restrictions, governance limitations or constraints on future integration.

In a competitive process, sellers may compare bidders not only on price but also on regulatory risk. A buyer that can credibly manage Vifo timing and remedy risk may be more attractive than a buyer with a higher headline offer but uncertain clearance prospects.

Interaction with warranties, disclosure and diligence

Vifo and public-interest sensitivity should also affect warranties and disclosure.

The seller may need to warrant the accuracy of information about the target’s activities, technology, customers, licences, government contracts, data, export controls and regulatory communications. The buyer may need specific disclosure on sensitive technology, public-sector relationships, supply-chain dependencies or prior authority contact.

If diligence reveals an issue that could affect screening, the parties should decide whether it belongs in the disclosure letter, a condition precedent, a covenant, a special indemnity or a termination right.

The key is to avoid treating regulatory sensitivity as a separate memo disconnected from the SPA.

Post-closing governance

Vifo-sensitive transactions may require post-closing commitments or governance restrictions. These may relate to information access, data localisation, board composition, security protocols, continuity of supply, customer contracts, reporting obligations or restrictions on transferring technology or assets.

Those commitments must be implemented in the Dutch BV documents and governance process. It may not be enough to accept them in correspondence with the authorities. The buyer must be able to operate the target in compliance with any conditions.

This may require board rules, reserved matters, authority matrices, information protocols, intercompany agreements, IP licences, compliance policies and customer communications.

Practical drafting point

In Vifo-sensitive Dutch acquisitions, the SPA should not merely say “regulatory approvals are a condition precedent”. It should allocate the process risk.

Who files? Who controls the strategy? What information must be provided? What remedies must be accepted? When can a party terminate? What happens if approval is conditional? How are sensitive information and pre-closing control handled? How are post-closing commitments implemented?

Those are transaction points, not only regulatory points.

FAQ

What is Vifo screening?
Vifo screening is Dutch investment screening for certain acquisitions and investments that may affect national security, particularly around vital providers, sensitive technology and related strategic interests.

Is Vifo only relevant for non-EU buyers?
No. The practical risk may be higher in some foreign-buyer contexts, but the analysis depends on the transaction, target activities, influence acquired and applicable legal framework.

When should Vifo be analysed?
At the start of the deal process. It can affect due diligence, SPA drafting, conditions precedent, long-stop dates, financing and closing mechanics.

How does Vifo affect the SPA?
It may require specific conditions precedent, cooperation covenants, information undertakings, remedy obligations, termination rights and post-closing commitments.

Can Vifo sensitivity affect minority investments?
Yes, depending on the level of influence, the target’s activities and the rights acquired by the investor.

About Dirk de Waard

Dirk de Waard is a Dutch corporate / M&A lawyer, partner at Venture Lawyers in Amsterdam, and advises foreign buyers, investors, sellers, founders and international counsel on Dutch acquisitions, Vifo-sensitive transactions, SPA drafting, governance and cross-border deal implementation.

Is Vifo risk properly reflected in your Dutch acquisition?

Vifo screening and public-interest sensitivity can affect timing, conditions precedent, information access, buyer covenants, closing certainty and post-closing governance. These issues should be addressed before the SPA is signed.

Dirk de Waard advises buyers, sellers and international counsel on Dutch M&A transactions involving foreign investors, sensitive technology and public-interest deal risk. Contact Dirk de Waard at dirk.dewaard@viottalaw.com to align the Vifo workstream with your SPA and closing timetable.